David P Fairlie Selected Research

Anaphylatoxin C5a Receptor

1/2017	The Ribosomal Protein S19 Suppresses Antitumor Immune Responses via the Complement C5a Receptor 1.
7/2014	Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche.
6/2004	Protective effect of a human C5a receptor antagonist against hepatic ischaemia-reperfusion injury in rats.
6/2004	Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury.
1/2004	Protective effects of a potent C5a receptor antagonist on experimental acute limb ischemia-reperfusion in rats.
11/2003	A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease.
1/2003	A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats.
9/2002	Antiarthritic activity of an orally active C5a receptor antagonist against antigen-induced monarticular arthritis in the rat.
4/2002	Protective effect of a new C5a receptor antagonist against ischemia-reperfusion injury in the rat small intestine.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David P Fairlie Research Topics

Disease

33	Neoplasms (Cancer) 01/2021 - 06/2004
26	Inflammation (Inflammations) 03/2022 - 01/2005
20	Infections 01/2022 - 01/2005
10	Malaria 01/2022 - 02/2006
7	Obesity 01/2017 - 02/2010
6	Bacterial Infections (Bacterial Infection) 01/2022 - 12/2015
6	Colitis 01/2021 - 11/2003
6	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021 - 11/2003
6	Fibrosis (Cirrhosis) 10/2019 - 04/2010
6	Arthritis (Polyarthritis) 02/2016 - 09/2002
6	Edema (Dropsy) 07/2012 - 04/2002
6	Reperfusion Injury 01/2009 - 04/2002
5	Breast Neoplasms (Breast Cancer) 01/2018 - 07/2014
4	Neoplasm Metastasis (Metastasis) 01/2021 - 07/2014
4	Type 2 Diabetes Mellitus (MODY) 02/2017 - 05/2015
4	Ischemia 08/2007 - 04/2002
3	Melanoma (Melanoma, Malignant) 11/2020 - 12/2006
3	Pain (Aches) 01/2018 - 12/2010
3	Metabolic Diseases (Metabolic Disease) 01/2016 - 01/2012
3	Parasitic Diseases (Parasitic Disease) 12/2015 - 11/2006
3	Bone Resorption 09/2015 - 07/2006
3	Body Weight (Weight, Body) 12/2013 - 05/2005
3	Stroke (Strokes) 06/2013 - 08/2007
3	Wounds and Injuries (Trauma) 06/2004 - 04/2002
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2021 - 09/2012
2	Proteinuria 01/2021 - 01/2004
2	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 01/2017
2	Thrombosis (Thrombus) 01/2021 - 01/2006
2	Colonic Neoplasms (Colon Cancer) 01/2021 - 01/2018
2	Multiple Myeloma 11/2020 - 12/2015
2	Leukemia 11/2020 - 06/2015
2	Liver Cirrhosis (Hepatic Cirrhosis) 10/2019 - 01/2018
2	Necrosis 09/2019 - 05/2005
2	Parkinson Disease (Parkinson's Disease) 01/2019 - 01/2015
2	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2018 - 01/2018
2	Parasitemia 01/2017 - 02/2006
2	Weight Loss (Weight Reduction) 01/2017 - 02/2012
2	Disease Progression 02/2016 - 02/2012
2	Experimental Arthritis 02/2016 - 07/2012
2	Communicable Diseases (Infectious Diseases) 01/2016 - 01/2012
2	Virus Diseases (Viral Diseases) 01/2016 - 11/2004
2	Falciparum Malaria (Plasmodium falciparum Malaria) 12/2015 - 01/2012
2	Insulin Resistance 10/2015 - 12/2013
2	Cardiovascular Diseases (Cardiovascular Disease) 09/2015 - 01/2009

Drug/Important Bio-Agent (IBA)

19	Histone Deacetylase InhibitorsIBA 01/2022 - 06/2004
14	Histone Deacetylases (Histone Deacetylase)IBA 03/2022 - 12/2006
14	Pharmaceutical PreparationsIBA 01/2022 - 11/2003
12	CytokinesIBA 01/2022 - 04/2010
11	Proteins (Proteins, Gene)FDA Link 03/2022 - 01/2004
10	Peptide Hydrolases (Proteases)FDA Link 01/2021 - 11/2004
10	PAR-2 ReceptorIBA 01/2021 - 10/2007
10	Peptides (Polypeptides)IBA 01/2021 - 11/2004
10	Complement System Proteins (Complement)IBA 01/2018 - 04/2002
9	AntigensIBA 01/2022 - 09/2002
9	EnzymesIBA 01/2022 - 05/2005
9	Anaphylatoxin C5a ReceptorIBA 01/2017 - 04/2002
8	LigandsIBA 01/2021 - 01/2005
8	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2019 - 01/2006
7	CollagenIBA 10/2019 - 06/2006
6	VaccinesIBA 12/2021 - 11/2006
6	Histones (Histone)IBA 12/2021 - 06/2004
6	Vorinostat FDA Link 01/2021 - 04/2010
5	5- (2- oxopropylideneamino)- 6- d- ribitylaminouracilIBA 01/2021 - 11/2019
5	Peroxidase (Myeloperoxidase)IBA 02/2012 - 01/2003
4	Glucose (Dextrose)FDA LinkGeneric 07/2021 - 02/2013
4	Transcription Factors (Transcription Factor)IBA 01/2021 - 01/2009
4	CalciumIBA 01/2020 - 02/2012
4	ChemokinesIBA 01/2020 - 09/2015
4	CarbohydratesIBA 09/2015 - 09/2012
4	Antimalarials (Antimalarial Agents)IBA 07/2014 - 01/2012
4	Secretory Phospholipases A2IBA 07/2006 - 09/2003
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2004 - 04/2002
3	Riboflavin (Vitamin B2)FDA LinkGeneric 01/2022 - 12/2015
3	Antiviral Agents (Antivirals)IBA 12/2021 - 01/2016
3	TrypsinIBA 01/2021 - 02/2012
3	Biomarkers (Surrogate Marker)IBA 01/2018 - 12/2013
3	Complement C5a (Complement 5a)IBA 01/2017 - 11/2011
3	Lysine (L-Lysine)FDA Link 01/2017 - 01/2012
3	AcPhe(ornithine- Pro- cyclohexylamine- Trp- Arg)IBA 01/2004 - 04/2002
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 09/2003 - 04/2002
2	Interleukin-23 (Interleukin 23)IBA 01/2022 - 11/2019
2	Granzymes (Granzyme)IBA 12/2021 - 01/2016
2	PerforinIBA 01/2021 - 01/2018
2	Proteinase-Activated ReceptorsIBA 01/2021 - 01/2006
2	AntibodiesIBA 01/2020 - 12/2019
2	Glucagon-Like Peptide 1 (GLP 1)IBA 02/2017 - 01/2016
2	belinostatIBA 01/2017 - 12/2015
2	romidepsin (FK228)FDA Link 01/2017 - 12/2015
2	PanobinostatIBA 01/2017 - 12/2015
2	Interleukin-6 (Interleukin 6)IBA 02/2016 - 10/2015
2	Glucagon-Like Peptide-1 ReceptorIBA 01/2016 - 05/2015
2	Insulin (Novolin)FDA Link 10/2015 - 02/2013
2	FatsIBA 09/2015 - 09/2012
2	NociceptinIBA 01/2015 - 12/2010
2	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 03/2013 - 01/2012
2	Group II Phospholipases A2IBA 09/2012 - 05/2005

Therapy/Procedure

14	Therapeutics 01/2020 - 08/2007
3	Immunotherapy 12/2020 - 07/2014
2	Drug Therapy (Chemotherapy) 01/2017 - 06/2004
2	Oral Administration 09/2015 - 02/2012